KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Net Margin (2016 - 2025)

TherapeuticsMD's Net Margin history spans 16 years, with the latest figure at 0.78% for Q4 2025.

  • For Q4 2025, Net Margin fell 2147.0% year-over-year to 0.78%; the TTM value through Dec 2025 reached 2.78%, down 466.0%, while the annual FY2025 figure was 2.78%, 466.0% down from the prior year.
  • Net Margin reached 0.78% in Q4 2025 per TXMD's latest filing, down from 13.01% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 36538.51% in Q2 2022 to a low of 4481.44% in Q1 2022.
  • Average Net Margin over 5 years is 1259.45%, with a median of 4.33% recorded in 2025.
  • The largest YoY upside for Net Margin was 3672394bps in 2022 against a maximum downside of -428320bps in 2022.
  • A 5-year view of Net Margin shows it stood at 268.5% in 2021, then crashed by -84bps to 42.66% in 2022, then skyrocketed by 207bps to 131.08% in 2023, then plummeted by -84bps to 20.69% in 2024, then crashed by -104bps to 0.78% in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Net Margin are 0.78% (Q4 2025), 13.01% (Q3 2025), and 0.63% (Q2 2025).